These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 20109515)

  • 21. Characterization of domain-peptide interaction interface: a case study on the amphiphysin-1 SH3 domain.
    Hou T; Zhang W; Case DA; Wang W
    J Mol Biol; 2008 Feb; 376(4):1201-14. PubMed ID: 18206907
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evidence for SH3 domain directed binding and phosphorylation of Sam68 by Src.
    Shen Z; Batzer A; Koehler JA; Polakis P; Schlessinger J; Lydon NB; Moran MF
    Oncogene; 1999 Aug; 18(33):4647-53. PubMed ID: 10467411
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rational design of specific high-affinity peptide ligands for the Abl-SH3 domain.
    Pisabarro MT; Serrano L
    Biochemistry; 1996 Aug; 35(33):10634-40. PubMed ID: 8718852
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular interactions of the Src homology 2 domain protein Shb with phosphotyrosine residues, tyrosine kinase receptors and Src homology 3 domain proteins.
    Karlsson T; Songyang Z; Landgren E; Lavergne C; Di Fiore PP; Anafi M; Pawson T; Cantley LC; Claesson-Welsh L; Welsh M
    Oncogene; 1995 Apr; 10(8):1475-83. PubMed ID: 7537362
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alternative mode of binding to phosphotyrosyl peptides by Src homology-2 domains.
    Qin C; Wavreille AS; Pei D
    Biochemistry; 2005 Sep; 44(36):12196-202. PubMed ID: 16142918
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disrupting the intramolecular interaction between proto-oncogene c-Src SH3 domain and its self-binding peptide PPII with rationally designed peptide ligands.
    Zhou P; Hou S; Bai Z; Li Z; Wang H; Chen Z; Meng Y
    Artif Cells Nanomed Biotechnol; 2018 Sep; 46(6):1122-1131. PubMed ID: 28754059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular recognition properties of FN3 monobodies that bind the Src SH3 domain.
    Karatan E; Merguerian M; Han Z; Scholle MD; Koide S; Kay BK
    Chem Biol; 2004 Jun; 11(6):835-44. PubMed ID: 15217616
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitative analysis of Grb2-Sos1 interaction: the N-terminal SH3 domain of Grb2 mediates affinity.
    Sastry L; Lin W; Wong WT; Di Fiore PP; Scoppa CA; King CR
    Oncogene; 1995 Sep; 11(6):1107-12. PubMed ID: 7566970
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The crystal structure of the N-terminal SH3 domain of Grb2.
    Guruprasad L; Dhanaraj V; Timm D; Blundell TL; Gout I; Waterfield MD
    J Mol Biol; 1995 May; 248(4):856-66. PubMed ID: 7752246
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutational investigation of the specificity determining region of the Src SH2 domain.
    Bradshaw JM; Mitaxov V; Waksman G
    J Mol Biol; 2000 Jun; 299(2):521-35. PubMed ID: 10860756
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Examining the specificity of Src homology 3 domain--ligand interactions with alkaline phosphatase fusion proteins.
    Yamabhai M; Kay BK
    Anal Biochem; 1997 Apr; 247(1):143-51. PubMed ID: 9126384
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design and biological evaluation of linear and cyclic phosphopeptide ligands of the N-terminal SH2 domain of protein tyrosine phosphatase SHP-1.
    Imhof D; Wieligmann K; Hampel K; Nothmann D; Zoda MS; Schmidt-Arras D; Zacharias M; Böhmer FD; Reissmann S
    J Med Chem; 2005 Mar; 48(5):1528-39. PubMed ID: 15743195
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of a novel series of potent and selective substrate-based inhibitors of p60c-src protein tyrosine kinase: conformational and topographical constraints in peptide design.
    Alfaro-Lopez J; Yuan W; Phan BC; Kamath J; Lou Q; Lam KS; Hruby VJ
    J Med Chem; 1998 Jun; 41(13):2252-60. PubMed ID: 9632358
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Studying receptor-ligand interactions using encoded amino acid scanning.
    Camarero JA; Ayers B; Muir TW
    Biochemistry; 1998 May; 37(20):7487-95. PubMed ID: 9585562
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting the SH3 domain of human osteoclast-stimulating factor with rationally designed peptoid inhibitors.
    Han S; Liu Q; Wang F; Yuan Z
    J Pept Sci; 2016 Aug; 22(8):533-9. PubMed ID: 27443979
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phage display selection of ligand residues important for Src homology 3 domain binding specificity.
    Rickles RJ; Botfield MC; Zhou XM; Henry PA; Brugge JS; Zoller MJ
    Proc Natl Acad Sci U S A; 1995 Nov; 92(24):10909-13. PubMed ID: 7479908
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acquisition of Fyn-selective SH3 domain ligands via a combinatorial library strategy.
    Li H; Lawrence DS
    Chem Biol; 2005 Aug; 12(8):905-12. PubMed ID: 16125102
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of either 4-R-hydroxyproline or 4-R-fluoroproline on the conformation and SH3m-cort binding of HPK1 proline-rich peptide.
    Borgogno A; Ruzza P
    Amino Acids; 2013 Feb; 44(2):607-14. PubMed ID: 22976002
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Atomic resolution structures of the c-Src SH3 domain in complex with two high-affinity peptides from classes I and II.
    Bacarizo J; Camara-Artigas A
    Acta Crystallogr D Biol Crystallogr; 2013 May; 69(Pt 5):756-66. PubMed ID: 23633584
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification and characterization of Src SH3 ligands from phage-displayed random peptide libraries.
    Sparks AB; Quilliam LA; Thorn JM; Der CJ; Kay BK
    J Biol Chem; 1994 Sep; 269(39):23853-6. PubMed ID: 7929027
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.